Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (June 2022)
27 slides from Sutro Biopharma's investor presentation, Jun 28, 2022
Slide 1: Company Overview June 2022
Company Overview June 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Sutro is a Clinical-Stage Oncology Company Pioneering Next-Generation Novel Format ADCs
STRO-002 Phase 1 data show encouraging efficacy across a wide range of ovarian cancer patients with diverse FolRα expression levels. Platform Platform enabled the first bispecific ADC in the clinic and allows for the novel dual-drug conjugation modality, immunostimulatory ADCs (iADCs). Collaboration
Slide 4: Cell-Free Platform Allows for Rapid and Iterative Design and Evaluation
Cell-Free Platform Allows for Rapid and Iterative Design and Evaluation Toolkit of modular properties provides flexibility to engineer potential best-in-class and next-generation ADCs Structure- Activity Relationship Rapid and iterative process to optimize for specificity and optimal therapeutic ind
Slide 5: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)
New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Featuring dual drug conjugation technology with both cytotoxin and immune modulator $90M upfront to develop iADCs for up to three targets. $422.5M in development, regulatory and commercial milestones for each product cand
Slide 6: Six Product Candidates in Clinical Development Were Enabled by Sutro's Platform
Six Product Candidates in Clinical Development Were Enabled by Sutro’s Platform Unique engineering prowess in the field of complex conjugated antibodies Modality Program Target(s) Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Antibody-Drug Conjugate (ADC) STRO-002 FolRα Ovarian Cance
Slide 7: Achievements and Milestones
Achievements and Milestones Clinical data readouts and partnerships provide multiple anticipated 2022 value drivers for Sutro STRO-002, FolRα ADC Greater China deal with Tasly (Dec. 2021) Ovarian cancer dose-expansion interim data (Jan. 2022) EOP1/2 meeting (Mid-2022) Anticipated dose-expansion data
Slide 8: FolRα-Targeting ADC: STRO-002
FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002
Slide 9: Highly optimized ADC designed to drive efficient tumor responses
Highly optimized ADC designed to drive efficient tumor responses across a broad range of target antigen levels STRO 002 (1) Sutro-proprietary tubulin-targeting 3-aminophenol hemiasterlin warhead, SC209. (2) Based on STRO-002 pre-clinical models showing immune stimulation at site of tumor upon cell d
Slide 10: Phase 1 Study in Patients with Advanced Ovarian Cancer
Phase 1 Study in Patients with Advanced Ovarian Cancer Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy STRO 002 Protocol Baseline Characteristics Inclusive of all FolRα expression levels; tissue samples voluntary and samples received from <50% of patient
Slide 11: Patient Characteristics in Dose Expansion Cohort
Patient Characteristics in Dose Expansion Cohort Interim data for dose expansion are as of November 8, 2021 STRO 002 Dose Expansion Patient Baseline Characteristics Randomized Dose Levels Ovarian Cancer Patients 4.3 mg/kg N=23 5.2 mg/kg N=20 Total N=43 Median age, years (range) 63 (39–91) 56 (40–72)
Slide 12: Dose Response Demonstrated
Dose Response Demonstrated Interim data suggest that 5.2 mg/kg starting dose leads to higher response rates 20% -30% 2 pts had 0% Δ Maximum Change in Tumor Target Lesions (N=33) Partial Response 4.3 mg/kg 5.2 mg/kg Treatment ongoing as of Nov 8, 2021 PR confirmed by next scheduled scan (after Nov. 8
Slide 13: Objective Response by RECIST v1.1
Objective Response by RECIST v1.1 33% ORR rate in all 33 evaluable patients, unenriched for FolRα expression Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers Evaluable patients N=16 N=17 N=33 PR 3 4 7 PR confirmed by next scheduled scan post Nov. 8, 2021 0 4 4 Total PR 3 8 11
Slide 14: Robust Anti-tumor Activity and Disease Control Demonstrated
Robust Anti-tumor Activity and Disease Control Demonstrated Responders experienced rapid tumor reduction or a steady deepening of response Dose Expansion STRO 002 Change from baseline (%) Weeks since first treatment 20 -30 -100 0 Change in Sum of Diameters for Target Lesions Over Time (N=33) Startin
Slide 15: Encouraging Response Rates and Preliminary Data on Durability
Encouraging Response Rates and Preliminary Data on Durability Interim data suggest initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Initial data show partial responses confirmed & maintained following dose adjustment Median Duration
Slide 16: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level
Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level Ongoing Partial Response with 72% reduction in tumor burden Dose Expansion STRO 002 Initial diagnosis: Stage IV ovarian cancer, Jan 2020 3 Prior Regimens: Resistant to 1st Neoadjuvant / adjuvant Carbo / Taxol / Taxotere Refrac
Slide 17: TPS Identified as Scoring Algorithm Appropriate for STRO-002
TPS Identified as Scoring Algorithm Appropriate for STRO-002 Exploratory analysis suggests TPS > 25% correlated with higher response Patients at the 5.2 mg/kg starting dose and TPS > 25% demonstrated 53.8% ORR (n=13) ORR by TPS Expression Levels (Total Samples N=33) Dose Expansion STRO 002 TPS Overa
Slide 18: Emerging Safety Profile is Manageable
Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2 No new safety signals were observed, including the absence of keratopathy 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n (
Slide 19: Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy
Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy Emerging data inform potential starting dose and enrichment strategy Patients at the 5.2 mg/kg starting dose and TPS > 25% demonstrated 53.8% ORR (7/13) Dose Expansion STRO 002 Total of 11 confirmed PR (1) out of 33 RECIST v
Slide 20: Progressing & Expanding the STRO-002 Franchise
Progressing & Expanding the STRO-002 Franchise Additional clinical studies in ovarian & endometrial, and nonclinical work on other tumor types Dose-escalation cohort 39 patients, enrollment completed August 2020 Dose-expansion cohort 44 patients enrolled in US and Spain sites, enrollment completed N
Slide 21: CD74-Targeting ADC: STRO-001
CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 22: Potential First-in-Class Molecule for Patients with NHL and MM
Potential First-in-Class Molecule for Patients with NHL and MM STRO 001 Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects CD74 pAMF F404 Non-cleavable linker Maytansinoid warhead STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody rat
Slide 23: STRO-001-BCM1 Study Design and Updates
STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose escalation study with NHL update at ASH 2020 R/R multiple myeloma (N=30) R/R NHL (N=30) Cohort A Cohort B RP2D RP2D STRO-001-BCM1 Dose Escalation Study NHL Cohort Update at ASH 2020 A total of 21 patients have been treated with STRO-001 and
Slide 24: ASH 2020 Update in NHL Cohort
ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) Age, median (range), years 64.5 (21–82) Time from diagnosis, median (range), years 6.0 (1.0–29.8) NHL subtype, n (%) 21 (100) DLBCL 7 (33) Follicular lymphoma 7
Slide 25: Encouraging Interim Treatment Duration and Responses
Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T Responses to STRO-001 Treatment Duration Best Response Patients, n STRO-001 Dose NHL subtype CR 1 0.075 mg/kg DLBCL PR 2 0.65, 1.27 mg/kg DLBCL SD 3 1.27, 1.78, 2.5 mg/kg Marginal
Slide 26: Financial Overview
Financial Overview Well capitalized through cash and other financial sources $192.1M in cash, cash equivalents & marketable securities as of March 31, 2022 Projected cash runway into 1H 2024(1), based on current business plans and assumptions ~1.6M shares of Vaxcyte (Nasdaq: PCVX) not included in th
Slide 27: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD President of Research and Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini, MBA Chief Financial Officer Shabbir Anik, PhD Chief Technical